Physician profile
Jeremy Ryan Stapleton
NPI 1609905462
$6,684.78
in general payments reported to CMS, 2019-2025
26 companies · $1,557 in 2025
The $1,557 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $822 · 2020: $359 · 2021: $1,034 · 2022: $1,015 · 2023: $953 · 2024: $944 · 2025: $1,557.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,454.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,454.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,765.85 | 2019-2025 | Skyrizi, Rinvoq, Linzess |
| Takeda Pharmaceuticals U.S.A., INC. | $1,283.55 | 2019-2025 | Entyvio |
| Pfizer INC. | $827.49 | 2019-2025 | |
| Gilead Sciences, INC. | $676.80 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $566.87 | 2019-2025 | Xifaxan, Trulance, Uceris |
| Janssen Biotech, INC. | $388.20 | 2021-2022 | |
| Ardelyx, INC. | $136.81 | 2022-2025 | Ibsrela |
| Aimmune Therapeutics, INC. | $112.75 | 2024-2025 | Zenpep |
| Celgene Corporation | $108.91 | 2021-2023 | Zeposia |
| Phathom Pharmaceuticals, INC. | $105.54 | 2025 | Voquezna |
| Regeneron Healthcare Solutions, INC. | $94.43 | 2023-2025 | Dupixent |
| Qol Medical, LLC | $93.62 | 2021-2025 | Sucraid |
| Redhill Biopharma INC. | $82.62 | 2020-2023 | |
| Nestle Healthcare Nutrition INC. | $74.84 | 2023 | |
| Merck Sharp & Dohme LLC | $60.27 | 2021 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axonics, INC. | $48.80 | 2022 | |
| Shionogi INC | $40.41 | 2019-2020 | |
| Novo Nordisk INC | $35.43 | 2025 | Wegovy |
| Lilly USA, LLC | $33.44 | 2025 | Omvoh |
| Braintree Laboratories, INC. | $29.32 | 2021 | |
| Alnylam Pharmaceuticals INC. | $28.97 | 2023 | Givlaari |
| Evoke Pharma, INC. | $26.94 | 2020-2021 | |
| Celltrion USA INC. | $22.95 | 2025 | Vegzelma |
| Actelion Pharmaceuticals US, INC. | $14.29 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.09 | 2023 | Cyltezo |
| Allergan, INC. | $11.59 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeremy Stapleton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.